Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-05-11 @ 3:58 PM
Study NCT ID:
NCT05207735
Status:
UNKNOWN
Last Update Posted:
2022-01-26
First Post:
2021-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.
Sponsor:
Henan Cancer Hospital
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
2021-246
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None